Table 4 Outcomes and the medications administered in AAV patients during follow-up
AAV patients | Values |
|---|---|
Clinical outcomes during follow-up (N, (%)) | |
 All-cause mortality (N, (%)) | 18 (10.8) |
 Follow-up duration based on all-cause mortality (months) | 33.7 (65.6) |
 CVA (N, (%)) | 16 (9.6) |
 Follow-up duration based on CVA (months) | 30.5 (64.0) |
 CVD (N, (%)) | 14 (8.4) |
 Follow-up duration based on CVD (months) | 32.8 (63.6) |
Medications administered during follow-up (N, (%)) | |
 Glucocorticoid | 155 (92.8) |
 Cyclophosphamide | 87 (52.1) |
 Rituximab | 29 (17.4) |
 Azathioprine | 82 (49.1) |
 Mycophenolate mofetil | 22 (13.2) |
 Tacrolimus | 11 (6.6) |
 Methotrexate | 12 (7.2) |